pharma news today glp-1 obesity Prescriptions Quadruple Since 2021 Alongside Decline In GLP-1 Agonists Weight Loss Drugs

doi:10.1007/s00125-008-1149-y Buteau J

Retatrutide is a triple agonist (GLP-1, GIP, and glucagon)

In an eight-week placebo-controlled study of 60 women with BMIs from 25 to 28, those taking 176.5 mg per day of Satiereala type of saffron extractshowed greater reductions in snacking frequency and body weight compared to the placebo group

The 1mg dose also serves a critical role as the universal starting point for all titration schedules

Even with insurance, weight loss injectables can still cost hundreds of dollars per month

The NAD(+) precursor nicotinamide riboside enhances oxidative metabolism and protects against high-fat diet-induced obesity